Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMA-HF and HAI-HF in de Novo Heart Failure
NCT07243119Phase 4Enrolling by invitation
- Sponsor
- Regionshospitalet Gødstrup
- Start
- Dec 2025
- Primary completion
- Apr 2029
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of adenosine in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Regionshospitalet Gødstrup. Primary endpoints: Left ventricular ejection fraction at 3 months and Stress Myocardial Blood Flow. Started Dec 2025; status: enrolling by invitation.
02
Drugs
adenosine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07243119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07243119.